Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.88
MELA's Cash to Debt is ranked higher than
76% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. MELA: 2.88 )
MELA' s 10-Year Cash to Debt Range
Min: 2.83   Max: No Debt
Current: 2.88

Equity to Asset 0.63
MELA's Equity to Asset is ranked higher than
73% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. MELA: 0.63 )
MELA' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.94
Current: 0.63

0.37
0.94
F-Score: 4
Z-Score: -10.73
M-Score: 0.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2555.21
MELA's Operating margin (%) is ranked lower than
56% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. MELA: -2555.21 )
MELA' s 10-Year Operating margin (%) Range
Min: -8174.46   Max: -869.05
Current: -2555.21

-8174.46
-869.05
Net-margin (%) -2092.80
MELA's Net-margin (%) is ranked lower than
56% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.99 vs. MELA: -2092.80 )
MELA' s 10-Year Net-margin (%) Range
Min: -8155.76   Max: -1085.71
Current: -2092.8

-8155.76
-1085.71
ROE (%) -150.63
MELA's ROE (%) is ranked lower than
53% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. MELA: -150.63 )
MELA' s 10-Year ROE (%) Range
Min: -233.02   Max: -53.54
Current: -150.63

-233.02
-53.54
ROA (%) -87.50
MELA's ROA (%) is ranked lower than
54% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. MELA: -87.50 )
MELA' s 10-Year ROA (%) Range
Min: -502.58   Max: -50.87
Current: -87.5

-502.58
-50.87
ROC (Joel Greenblatt) (%) -338.29
MELA's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. MELA: -338.29 )
MELA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4892.42   Max: -403.68
Current: -338.29

-4892.42
-403.68
EBITDA Growth (%) -13.20
MELA's EBITDA Growth (%) is ranked higher than
60% of the 221 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. MELA: -13.20 )
MELA' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -1
Current: -13.2

EPS Growth (%) -10.00
MELA's EPS Growth (%) is ranked higher than
61% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. MELA: -10.00 )
MELA' s 10-Year EPS Growth (%) Range
Min: -28.9   Max: 34.6
Current: -10

-28.9
34.6
» MELA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MELA Guru Trades in

MELA Guru Trades in

MELA Guru Trades in

Q2 2012

MELA Guru Trades in Q2 2012

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MELA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-06-30 Sold Out 0.01%$25.1 - $47.4 $ 1.31-96%0
George Soros 2012-03-31 Reduce -80%0.13%$32.1 - $48.2 $ 1.31-97%20000
George Soros 2011-12-31 New Buy0.16%$35 - $66.2 $ 1.31-97%100000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.45
MELA's P/B is ranked higher than
98% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. MELA: 0.45 )
MELA' s 10-Year P/B Range
Min: 0.45   Max: 6.36
Current: 0.45

0.45
6.36
P/S 9.59
MELA's P/S is ranked higher than
52% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. MELA: 9.59 )
MELA' s 10-Year P/S Range
Min: 10.08   Max: 1330
Current: 9.59

10.08
1330
EV-to-EBIT 0.08
MELA's EV-to-EBIT is ranked higher than
100% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.42 vs. MELA: 0.08 )
MELA' s 10-Year EV-to-EBIT Range
Min: -4.7   Max: 0.1
Current: 0.08

-4.7
0.1
Current Ratio 5.19
MELA's Current Ratio is ranked higher than
87% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. MELA: 5.19 )
MELA' s 10-Year Current Ratio Range
Min: 1.31   Max: 25.52
Current: 5.19

1.31
25.52
Quick Ratio 3.84
MELA's Quick Ratio is ranked higher than
86% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. MELA: 3.84 )
MELA' s 10-Year Quick Ratio Range
Min: 0.79   Max: 25.52
Current: 3.84

0.79
25.52

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.27
MELA's Price/Net Cash is ranked higher than
99% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. MELA: 1.27 )
MELA' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 21.52
Current: 1.27

1.68
21.52
Price/Net Current Asset Value 0.84
MELA's Price/Net Current Asset Value is ranked higher than
99% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. MELA: 0.84 )
MELA' s 10-Year Price/Net Current Asset Value Range
Min: 1.11   Max: 37.65
Current: 0.84

1.11
37.65
Price/Tangible Book 0.45
MELA's Price/Tangible Book is ranked higher than
99% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.44 vs. MELA: 0.45 )
MELA' s 10-Year Price/Tangible Book Range
Min: 0.59   Max: 18.29
Current: 0.45

0.59
18.29
Price/Median PS Value 0.17
MELA's Price/Median PS Value is ranked higher than
99% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. MELA: 0.17 )
MELA' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 19.18
Current: 0.17

0.23
19.18
Earnings Yield (Greenblatt) 1250.00
MELA's Earnings Yield (Greenblatt) is ranked higher than
100% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. MELA: 1250.00 )
MELA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 669.3   Max: 39368.8
Current: 1250

669.3
39368.8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:E2ON.Germany,
Mela Sciences Inc was incorporated in the State of New York in December 1989 under the name Electro-Optical Sciences, Inc. and subsequently reincorporated under the laws of the State of Delaware in 1997. In April 2010, it changed its name to MELA Sciences, Inc. The Company is a medical device company focused on the commercialization of its flagship product, MelaFind, the further design and development of MelaFind and its technology. MelaFind is a non-invasive, point-of-care instrument to aid in the detection of melanoma. The MelaFind system produces a report at the point-of-care to assist in the diagnostic process. MelaFind employs light of multiple wavelengths to obtain data from clinically atypical lesions; and then the data are analyzed against its proprietary database of melanomas and benign lesions using its sophisticated algorithms. The Company competes with other imaging modalities, including molecular imaging in which tagged antibodies search for cancer cell antigens, and with molecular and genetic screening tests. The sale and marketing of MelaFind is subject to a complex system of federal and state laws and regulations intended to deter, detect, and respond to fraud and abuse in the healthcare system.
» More Articles for MELA

Headlines

Articles On GuruFocus.com
own Mar 20 2013 
The Barclays Triggers More Insider Buying Mar 13 2013 
ElectroOptical Sciences Inc Reports Operating Results (10-K) Mar 03 2011 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Nov 05 2010 
ElectroOptical Sciences Inc (MELA) CFO Richard I Steinhart buys 1,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc (MELA) CEO Joseph V Gulfo buys 5,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc (MELA) CEO Joseph V Gulfo buys 5,000 Shares Aug 12 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Aug 06 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) May 10 2010 
ElectroOptical Sciences Inc Reports Operating Results (10-Q) Nov 09 2009 

More From Other Websites
MELA Sciences Names Michael R. Stewart Its Next President and CEO Nov 28 2014
MELA Sciences To Report Third Quarter 2014 Financial Results on Wednesday, November 12 Nov 28 2014
MELA SCIENCES, INC. /NY Financials Nov 25 2014
MELA SCIENCES, INC. /NY Files SEC form 8-K, Change in Directors or Principal Officers Nov 19 2014
MELA Sciences Names Michael R. Stewart Its Next President and CEO Nov 19 2014
10-Q for MELA Sciences, Inc. Nov 18 2014
MELA SCIENCES, INC. /NY Files SEC form 10-Q, Quarterly Report Nov 14 2014
MELA Sciences Earnings Call scheduled for 4:30 pm ET today Nov 12 2014
MELA Sciences Reports Third Quarter 2014 Financial Results Nov 12 2014
Q3 2014 MELA Sciences Earnings Release - Time Not Supplied Nov 12 2014
MELA Sciences to Report Third Quarter 2014 Financial Results on Wednesday, November 12 Nov 05 2014
Outcomes Study Reports Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for... Oct 22 2014
Outcomes Study Reports Use of MelaFind Reduced Benign Biopsies by 61% in Patients at Risk for... Oct 21 2014
UPDATE: H.C. Wainwright & Co. Initiates Coverage On MELA Sciences On Commercialization Strategy... Aug 18 2014
MELA SCIENCES, INC. /NY Files SEC form 10-Q, Quarterly Report Aug 14 2014
MELA SCIENCES, INC. /NY Files SEC form 8-K, Financial Statements and Exhibits Aug 06 2014
MELA SCIENCES, INC. /NY Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 29 2014
MELA SCIENCES, INC. /NY Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... Jul 23 2014
MELA SCIENCES, INC. /NY Files SEC form 8-K, Material Modification to Rights of Security Holders,... Jul 10 2014
MELA Sciences initiates study on clinical impact of MelaFind on melanoma biopsy Jun 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK